SCYX
Scynexis Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
0.00%
SCYX weight · VTI
Scynexis has 1 disclosed supplier and 3 disclosed customers in SEC filings.
SentenceWe were dependent on Merck for the establishment of our intellectual property rights related to ibrexafungerp, and if Merck did not establish our intellectual property rights with sufficient scope to protect ibrexafungerp, we may have limited or no ability to assert intellectual property rights to ibrexafungerp.
SCYX 10-Kaccession 0001178253-26-000007
SentenceIbrexafungerp was licensed to GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK) in May 2023.
SCYX 10-Kaccession 0001178253-26-000007
We are dependent on our existing third-party collaboration with Hansoh to commercialize ibrexafungerp in the Greater China region, and if Hansoh is not successful in commercializing ibrexafungerp in these areas, we will lose a significant source of potential revenue.
SCYX 10-Kaccession 0001178253-26-000007
SentenceWe are dependent on our existing third-party collaboration with R-Pharm to commercialize ibrexafungerp in the Russian Federation and certain other countries, and if R-Pharm is not successful in commercializing ibrexafungerp in those countries, we will lose a significant source of potential revenue.
SCYX 10-Kaccession 0001178253-26-000007
Scynexis Inc
3.71
Largest filed tie
—
−88.54%
shares held · 10 largest managers
Expected move
Inputsspot 3.77exp Nov 20ATM strike 5ATM straddle 1.32IV 89%